ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tezepelumab

Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.

Drug pageTezepelumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 17, 202234 company-led studies, 9 open or runningNext primary completion: Jan 13, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only288 open or runningphase 4since Mar 17, 2022Jul 30, 2013Jan 13, 2027phase 3 · NCT06706817
Amgen50 open or runningphase 2since Jan 10, 2019Sep 18, 2008none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 3since Dec 11, 2025Dec 11, 2025Dec 2028phase 3 · NCT07302516

Also a collaborator on its studies: Fortrea and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2008First study: phase 1 study in Dermatitis, AtopicFirst studyNCT00757042 · 78 enrolled
  2. Sep 3, 2009Phase 1 study in Healthy VolunteersNCT00972179 · 49 enrolled
  3. Jul 21, 2011Phase 1 study in AsthmaNCT01405963 · 31 enrolled · Canada
  4. Jun 9, 2015Named tezepelumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MEDI9929
  5. Jan 10, 2019Phase 2 study in Dermatitis, AtopicNCT03809663 · 251 enrolled · United States, Australia, Canada and more
  6. Apr 5, 2021Phase 2 study in Chronic UrticariaNCT04833855 · 183 enrolled · United States, Canada, France and more

TargetBeta

TSLP →read by rule
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
felcorekibartGlaxoSmithKlinephase 39
SHR-1905Jiangsu HengRui Medicinephase 37
TQC2731Sino Biopharmaceuticalphase 37
WIN378rulewindward-biophase 22
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 5 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04833855Chronic Urticaria · United States, Canada, France and more2CompletedDec 20, 2022183
NCT03809663Dermatitis, Atopic · United States, Australia, Canada and more2TerminatedMay 12, 2020251
NCT01405963Asthma · Canada1CompletedApr 5, 201331
NCT00972179Healthy Volunteers1CompletedJan 9, 201149
NCT00757042Dermatitis, Atopic1CompletedJan 5, 201178

How it is read

Names in the registry

  • “Tezepelumab”, 23 entries
  • “Experimental: Tezepelumab”, 4 entries
  • “MEDI9929”, 2 entries
  • “tezepelumab (Arm1&Arm2)”, 1 entry
  • “Tezepelumab Dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.